Clinical trial
Phase II Study to Compare Fulvestrant (F) 500mg Plus Placebo vs F 500mg Plus Palbociclib as First Line Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer Sensitive to Endocrine Therapy. GEICAM/2014-12
NCT02690480 is registered in ClinicalTrials.gov with Spanish Breast Cancer Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study to Compare Fulvestrant (F) 500mg Plus Placebo vs F 500mg Plus Palbociclib as First Line Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer Sensitive to Endocrine Therapy. GEICAM/2014-12
- Lead sponsor
- Spanish Breast Cancer Research Group
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- February 17, 2016
- Completion date
- December 31, 2023
- Enrollment
- 189 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.